Major investment in regenerative medicine enters its last stage — and the money might run out before treatments are ready.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Change history
02 May 2017
An earlier version of this story erroneously located John Simpson in Washington DC.
Additional information
Related links
Related links
Related links in Nature Research
Stem cells: Hope on the line 2014-Jul-02
Funding windfall rescues abandoned stem-cell trial 2014-Jun-03
Stem-cell boss urges communication 2011-Jun-29
Stem cells: The impatient advocate 2010-Dec-01
Blog post: Scientific panel recommends changes to California’s stem cell institute
Related external links
Rights and permissions
About this article
Cite this article
Maxmen, A. California’s $3-billion bet on stem cells faces final test. Nature 544, 401–402 (2017). https://doi.org/10.1038/544401a
Published:
Issue date:
DOI: https://doi.org/10.1038/544401a
